Canada's largest pharmaceutical company, Apotex and Searchlight Pharma, one of Canada's fastest growing companies, announced that they have reached an agreement whereby Apotex will acquire Searchlight.
Mithra and Searchlight Pharma sign DONESTA® licensing agreement for Canada Mithra to receive EUR 1.5 million milestone payout as a result of the signing...
Searchlight Pharma Announces Suvexx® Launch in Europe, along with Deal Expansion to all E.U. Markets
Mithra and Searchlight Pharma Announce Donesta® Licensing Agreement for Canada
Sol-Gel to receive up to $11 million in upfront payments and regulatory and sales milestones for both drugs, combined, plus additional royalties ranging from low double-digits to...
Miravo Healthcare™ Announces Filing of Special Meeting Materials in respect of Arrangement with Searchlight Pharma Inc.
Nextstellis® contains estetrol (E4), the first new estrogen in a combined oral contraceptive in the Canadian market in 50 years
LIEGE, Belgium and MONTREAL , March 8, 2021 /CNW/ - Mithra and Searchlight Pharma announced today that Health Canada has approved Nextstellis ® , the first and only combined oral contraceptive (COC) product based on the unique native estrogen estetrol (E4). Once launched, E4 will be the first new estrogen in a COC in the Canadian market in over half a century, and will be the only COC alternative to ethinyl estradiol-based COC pills in Canada .